相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1559
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- University of Geneva researchers have created a revolutionary DNA-based drug delivery system that uses computer-like logic to target cancer cells with unprecedented precision. - The system employs a "two-factor authentication" approach, requiring both cancer markers to be present before activating the drug, significantly reducing damage to healthy cells. - Unlike traditional antibody-drug conjugates, the smaller DNA strands can penetrate tumors more effectively and carry multiple drug components simultaneously. - The technology represents a breakthrough in programmable medicine, with drugs that can "compute" and respond intelligently to biological signals within the body.
- Scientists at the University of Geneva and Geneva University Hospital have engineered CAR-T cells targeting both PTPRZ1 and Tenascin-C proteins to overcome glioblastoma's resistance to standard immunotherapies. - The dual-target approach demonstrated enhanced efficacy in mouse models by triggering inflammatory reactions that destroy cancer cells while avoiding damage to healthy tissue. - Researchers overcame CAR-T cell exhaustion by identifying and counteracting three markers of cell fatigue, significantly prolonging therapeutic effectiveness in preclinical studies. - Clinical trials are expected to begin within a year in Geneva and Lausanne, offering new hope for patients with this deadly brain cancer that has a five-year survival rate of less than 5 percent.
- Tonix Pharmaceuticals has dosed the first patient in the FOCUS study, evaluating intranasal potentiated oxytocin products TNX-1900 and TNX-2900 for arginine-vasopressin deficiency (AVP-D), a rare endocrine disorder formerly known as central diabetes insipidus. - The randomized, double-blind, placebo-controlled crossover pilot study at Massachusetts General Hospital will assess single-dose treatments at 6 IU and 24 IU on markers of anxiety, depression, and socioemotional functioning in AVP-D patients. - AVP-D patients often experience mental health and quality-of-life challenges not adequately addressed by current interventions, with the condition associated with oxytocin deficiency and adverse mental health outcomes. - The study aims to generate preliminary data to inform future larger-scale clinical trials of oxytocin replacement therapy for this patient population.
